Loading...
In 2013, Gilead Sciences launched Sovaldi, a hepatitis C cure, at $84,000 for a 12-week course — roughly $1,000 per pill. The drug actually worked: it cured over 95% of hepatitis C patients, eliminating a disease that had previously required decades of expensive management and often led to liver transplants costing $500,000 or more. By conventional cost-effectiveness analysis, $84,000 was a bargain compared to the lifetime cost of the disease. But the sticker price provoked outrage, congressional hearings, and a debate that exposed the fundamentally broken incentive structure of pharmaceutical pricing. The pricing logic operated on several mutually reinforcing layers. Drug companies invested heavily in R&D — Gilead spent roughly $11 billion developing Sovaldi (including the acquisition ...
Popular framing: Gilead charged an unconscionable price because pharmaceutical executives are greedy; better regulation or price controls would fix this. The 'Anchoring' effect: how $84k wasn't a 'mistake' but a deliberate move to reset the entire industry's pricing ceiling.
Structural analysis: Drug pricing in the US is a principal-agent cascade where each intermediary (insurer, PBM, hospital system, Congress) faces incentives misaligned with patient outcomes. The prohibition on Medicare negotiation, patent evergreening, and the absence of a reference pricing regime were not oversights — they were constructed by actors whose financial interests depended on preserving pricing opacity. The cobra effect applies: policies designed to incentivize drug development (patents, exclusivity) became mechanisms for unlimited extraction because the 'R&D cost recovery' justification was never structurally enforced. The 'Asymmetric Risk' of the negotiation—the patient has no 'walk-away' power, which is the definition of an efficient market.
Focusing on Gilead's greed obscures that any firm in its position would have made the same decision — the system selects for and rewards this behavior. Until the incentive architecture changes (reference pricing, negotiation power, conditional exclusivity tied to actual R&D costs), replacing individual actors changes nothing. The framing gap matters because moral outrage generates political energy but directs it at symptoms rather than the feedback loop that produces those symptoms.
